DNA demethylating agents and epigenetic therapy of cancer

Advances in Genetics

Volumn 70, Issue C, 2010, Pages 327-340

  Mani, Samson ^a   Herceg, Zdenko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE; HISTONE DEACETYLASE INHIBITOR; MICRORNA;

ANIMAL; BOOK; DNA METHYLATION; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; NEOPLASM; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE; DRUG EFFECTS; KNOCKOUT MOUSE; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA METHYLATION; EPIGENESIS, GENETIC; GENES, TUMOR SUPPRESSOR; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MICE; MICE, KNOCKOUT; MICRORNAS; NEOPLASMS; RNA INTERFERENCE;

EID: 77957367695     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380866-0.60012-5     Document Type: Book

References (74)

1. Altucci L., Minucci S. Epigenetic therapies in haematological malignancies: Searching for true targets. Eur. J. Cancer 2009, 45:1137-1145.
2. Belinsky S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 2004, 4:707-717.
3. Belinsky S.A., Klinge D.M., Stidley C.A., Issa J.P., Herman J.G., March T.H., Baylin S.B. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003, 63:7089-7093.
4. Bhalla K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 2005, 23:3971-3993.
5. Bicaku E., Marchion D.C., Schmitt M.L., Munster P.N. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res. 2008, 68:1513-1519.
6. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
7. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
8. Callinan P.A., Feinberg A.P. The emerging science of epigenomics. Hum. Mol. Genet. 2006, 15(Special No 1):R95-R101.
9. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999, 21:103-107.
10. Cashen A.F., Schiller G.J., O'Donnell M.R., DiPersio J.F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol. 2010, 28:556-561.
11. Davis A.J., Gelmon K.A., Siu L.L., Moore M.J., Britten C.D., Mistry N., Klamut H., D'Aloisio S., MacLean M., Wainman N., Ayers D., Firby P., et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs 2003, 21:85-97.
12. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
13. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
14. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4:143-153.
15. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
16. Flynn J., Fang J.Y., Mikovits J.A., Reich N.O. A potent cell-active allosteric inhibitor of murine DNA cytosine C5 methyltransferase. J. Biol. Chem. 2003, 278:8238-8243.
17. Foubister V. Drug reactivates genes to inhibit cancer. Drug Discov. Today 2003, 8:430-431.
18. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Perez-Rosado A., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
19. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V.R., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
20. Gilbert J., Gore S.D., Herman J.G., Carducci M.A. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin. Cancer Res. 2004, 10:4589-4596.
21. Graham J.S., Kaye S.B., Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur. J. Cancer 2009, 45:1129-1136.
22. Gravina G.L., Marampon F., Di Staso M., Bonfili P., Vitturini A., Jannini E.A., Pestell R.G., Tombolini V., Festuccia C. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate 2010.
23. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
24. Jaenisch R., Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat. Genet. 2003, 33(Suppl.):245-254.
25. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
26. Jiang Y.H., Bressler J., Beaudet A.L. Epigenetics and human disease. Annu. Rev. Genomics Hum. Genet. 2004, 5:479-510.
27. Johnson L., Cao X., Jacobsen S. Interplay between two epigenetic marks. DNA methylation and histone H3 lysine 9 methylation. Curr. Biol. 2002, 12:1360-1367.
28. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
29. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
30. Jones P.A., Martienssen R. A blueprint for a human epigenome project: The AACR human epigenome workshop. Cancer Res. 2005, 65:11241-11246.
31. Joung K.E., Kim D.K., Sheen Y.Y. Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells. Arch. Pharm. Res. 2004, 27:640-645.
32. Kim J.S., Jeung H.K., Cheong J.W., Maeng H., Lee S.T., Hahn J.S., Ko Y.W., Min Y.H. Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. Br. J. Haematol. 2004, 124:166-178.
33. Kim J.C., Shin E.S., Kim C.W., Roh S.A., Cho D.H., Na Y.S., Kim T.W., Kim M.B., Hyun Y.L., Ro S., Kim S.Y., Kim Y.S. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer. Anticancer Res. 2009, 29:3027-3034.
34. Klisovic D.D., Klisovic M.I., Effron D., Liu S., Marcucci G., Katz S.E. Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: A potential strategy for uveal melanoma. Melanoma Res. 2005, 15:147-153.
35. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3:253-266.
36. Laird P.W. Cancer epigenetics. Hum. Mol. Genet. 2005, 14(Spec No 1):R65-R76.
37. Laird P.W. Principles and challenges of genome-wide DNA methylation analysis. Nat. Rev. Genet. 2010, 11:191-203.
38. Lehnertz B., Ueda Y., Derijck A.A., Braunschweig U., Perez-Burgos L., Kubicek S., Chen T., Li E., Jenuwein T., Peters A.H. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr. Biol. 2003, 13:1192-1200.
39. Lin X., Asgari K., Putzi M.J., Gage W.R., Yu X., Cornblatt B.S., Kumar A., Piantadosi S., DeWeese T.L., De Marzo A.M., Nelson W.G. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 2001, 61:8611-8616.
40. Lin Z., Bazzaro M., Wang M.C., Chan K.C., Peng S., Roden R.B. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin. Cancer Res. 2009, 15:570-577.
41. Lund A.H., van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004, 18:2315-2335.
42. Mai A., Altucci L. Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol. 2009, 41:199-213.
43. Maier S., Olek A. Diabetes: A candidate disease for efficient DNA methylation profiling. J. Nutr. 2002, 132:2440S-2443S.
44. Marks P.A., Dokmanovic M. Histone deacetylase inhibitors: Discovery and development as anticancer agents. Expert Opin. Investig. Drugs 2005, 14:1497-1511.
45. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000, 92:1210-1216.
46. Marks P.A., Richon V.M., Kelly W.K., Chiao J.H., Miller T. Histone deacetylase inhibitors: Development as cancer therapy. Novartis Found Symp. 2004, 259:269-281.
47. Marquez V.E., Kelley J.A., Agbaria R., Ben-Kasus T., Cheng J.C., Yoo C.B., Jones P.A. Zebularine: A unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann. NY Acad. Sci. 2005, 1058:246-254.
48. Maslak P., Chanel S., Camacho L.H., Soignet S., Pandolfi P.P., Guernah I., Warrell R., Nimer S. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2006, 20:212-217.
49. McKinsey T.A., Olson E.N. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet. 2004, 20:206-213.
50. Nephew K.P., Huang T.H. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 2003, 190:125-133.
51. Noguchi M., Yokoyama M., Watanabe S., Uchiyama M., Nakao Y., Hara K., Iwasaka T. Inhibitory effect of the tea polyphenol, (-)-epigallocatechin gallate, on growth of cervical adenocarcinoma cell lines. Cancer Lett. 2006, 234:135-142.
52. Oehme I., Deubzer H.E., Wegener D., Pickert D., Linke J.P., Hero B., Kopp-Schneider A., Westermann F., Ulrich S.M., von Deimling A., Fischer M., Witt O. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. Cancer Res. 2009, 15:91-99.
53. Oki Y., Issa J.P. Review: Recent clinical trials in epigenetic therapy. Rev. Recent Clin. Trials 2006, 1:169-182.
54. Park S.J., Kim M.J., Kim H.B., Sohn H.Y., Bae J.H., Kang C.D., Kim S.H. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. Exp. Cell Res. 2009, 315:1809-1818.
55. Reid G., Metivier R., Lin C.Y., Denger S., Ibberson D., Ivacevic T., Brand H., Benes V., Liu E.T., Gannon F. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 2005, 24:4894-4907.
56. Rudek M.A., Zhao M., He P., Hartke C., Gilbert J., Gore S.D., Carducci M.A., Baker S.D. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J. Clin. Oncol. 2005, 23:3906-3911.
57. Sawan C., Vaissiere T., Murr R., Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutat. Res. 2008, 642:1-13.
58. Sekeres, M. A., List, A. F., Cuthbertson, D., Paquette, R., Ganetsky, R., Latham, D., Paulic, K., Afable, M., Saba, H. I., Loughran, T. P., Jr., and Maciejewski, J. P. (in press). Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J. Clin. Oncol.
59. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
60. Soppe W.J., Jasencakova Z., Houben A., Kakutani T., Meister A., Huang M.S., Jacobsen S.E., Schubert I., Fransz P.F. DNA methylation controls histone H3 lysine 9 methylation and heterochromatin assembly in Arabidopsis. EMBO J. 2002, 21:6549-6559.
61. Sorm F., Piskala A., Cihak A., Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964, 20:202-203.
62. Steensma D.P. Decitabine treatment of patients with higher-risk myelodysplastic syndromes. Leuk. Res. 2009, 33(Suppl. 2):S12-S17.
63. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
64. Ting A.H., Jair K.W., Suzuki H., Yen R.W., Baylin S.B., Schuebel K.E. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat. Genet. 2004, 36:582-584.
65. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., Ngo L., Holmgren A., Jiang X., Marks P.A. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102:673-678.
66. Urdinguio R.G., Sanchez-Mut J.V., Esteller M. Epigenetic mechanisms in neurological diseases: Genes, syndromes, and therapies. Lancet Neurol. 2009, 8:1056-1072.
67. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 2005, 5:223-231.
68. Vaissiere T., Sawan C., Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat. Res. 2008, 659:40-48.
69. van den Bosch J., Lubbert M., Verhoef G., Wijermans P.W. The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk. Res. 2004, 28:785-790.
70. Vigushin D.M., Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 2002, 13:1-13.
71. Villar-Garea A., Fraga M.F., Espada J., Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003, 63:4984-4989.
72. Xiao J.J., Foraker A.B., Swaan P.W., Liu S., Huang Y., Dai Z., Chen J., Sadee W., Byrd J., Marcucci G., Chan K.K. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J. Pharmacol. Exp. Ther. 2005, 313:268-276.
73. Yang H., Hoshino K., Sanchez-Gonzalez B., Kantarjian H., Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk. Res. 2005, 29:739-748.
74. Zhou X., Yang X.Y., Popescu N.C. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: Perspectives for therapeutics. Int. J. Oncol. 2010, 36:999-1005.